Background: A number of prognostically relevant clinicopathological variables have been proposed for pancreatic neuroendocrine neoplasms. However, a standardized prognostication system has yet to be established for patients undergoing potentially curative tumour resection.
Introduction
Pancreatic neuroendocrine neoplasms are rare tumours with an annual incidence of one to five per 100 000. 1, 2 Perhaps as a result of increased awareness and improved diagnostic capabilities, their prevalence has increased substantially over the last 25 years. 3 Although usually indolent, the biological behaviour of pancreatic neuroendocrine neoplasms ranges from benign to frankly malignant. However, classic criteria that define malignant behaviour, such as local invasion and presence of lymph node or distant metastases, have not always correlated with risk of recurrence and death. 4 A number of clinical and pathological parameters have been used to classify these neoplasms for prognostication and to define criteria for surgical therapy. Incorporation of staging variables (size, lymph node and distant metastases) and histological variables (presence of necrosis, secretory function, mitotic index, proliferative index, perineural invasion, vascular invasion) have resulted in accurate, but sometimes complex, classification schemes. 4, 5 Most of these have divided pancreatic neuroendocrine neoplasms into well-and poorly differentiated neoplasms; highgrade neuroendocrine carcinoma appears to be a separate disease entity with a poor prognosis regardless of treatment. 6 Previous analyses of resected pancreatic neuroendocrine neoplasms have included patients with metastatic and locally advanced tumours, or have excluded patients with hormonesecreting tumours. 4, 5, [7] [8] [9] [10] This heterogeneity is likely to render their findings less applicable to patients with resectable, localized disease. In this study, we analysed the individual, operative and pathological characteristics of patients with non-metastatic pancreatic neuroendocrine neoplasms undergoing potentially curative tumour resection. Our aim was to create a simplified, reproducible prognostication system to stratify this patient population according to risk for disease recurrence and death.
Materials and methods
Patients who underwent potentially curative resection of primary pancreatic neuroendocrine neoplasms at the University of Wisconsin School of Medicine and Public Health were identified from a prospectively maintained database after institutional review board approval. Potentially curative resection was defined as surgical removal of all macroscopic disease (R0 or R1 resection); patients undergoing repeat tumour resections and those with evidence of distant metastatic disease and/or locally advanced unresectable disease were excluded from analysis. Tumour location was determined preoperatively with computed tomography, magnetic resonance imaging and somatostatin receptor scintigraphy as deemed necessary by the treating physicians. Additional therapeutic modalities including chemotherapy and somatostatin analogue therapy were used at the discretion of treating physicians. Demographic and operative data were collected, and all pathological specimens were re-examined by a single pathologist (AGL) to confirm the diagnosis of pancreatic neuroendocrine neoplasm and to analyse histological characteristics. These included tumour size, location, perineural and vascular invasion, mitotic rate, necrosis, status of surgical margin and lymph node metastases. The lymph node ratio (LNR), defined as the ratio of malignant to total lymph nodes resected, was calculated for each patient. Neoplasms were classified as low grade (Յ2 mitoses per 50 highpower fields and no necrosis) or intermediate grade (>2 mitoses per 50 high-power fields and/or focal necrosis) according to previously defined criteria. 4 Patients were followed clinically and with tumour markers and cross-sectional imaging as deemed necessary. Medical record review and patient contact were performed to obtain information on survival and disease status. Disease recurrence was defined by radiographic evidence of new tumours. Overall survival (OS), disease-specific survival (DSS) and diseasefree survival (DFS) were calculated using the Kaplan-Meier method. Univariate analysis was performed with the log-rank test for categorical variables and with Cox regression analysis for continuous variables. Statistical significance was defined as P < 0.05. All variables found to have P < 0.1 by univariate analysis for either DSS or DFS were combined into potential three-or four-variable scoring systems in which one point was assigned for the presence of each potentially prognostic variable. Depending on the presence of each variable, scores lay in the range of 0-3 for threevariable systems and 0-4 for four-variable systems. The association between each possible scoring system combination and DSS and DFS was evaluated using the log-rank test. The predictive ability of the optimal prognostic scoring system to discriminate DSS and DFS outcomes was quantified using the Harrell's concordance index (c-index). 11 The c-index is calculated as the probability that, for each randomly generated pair of patients from a dataset, the patient with the favourable prognostic score survived longer than the patient with the unfavourable prognostic score. A prognostication system with a c-index of 1 indicates that the prognostic system predicted the correct outcome in all cases; a c-index of 0 implies that the incorrect outcome was predicted in all cases, and a c-index of 0.5 means that the system correctly predicted the outcome 50% of the time (in effect, demonstrating no predictive ability). Non-informative pairs (e.g. pairs for whom survival was equal or in which the survivor had a shorter follow-up interval) were not included in the calculation of the c-index.
Results

Patient characteristics
A total of 43 patients underwent potentially curative tumour resection of non-metastatic pancreatic neuroendocrine neoplasms between 1991 and 2007. The majority of patients were female and most tumours were localized in the pancreatic body and tail (Table 1) .
Perioperative characteristics
Median postoperative length of hospital stay was 7 days (range 3-28 days). The majority of patients underwent formal pancreatic resections for tumour extirpation. Most patients underwent R0 resections and no perioperative mortalities were encountered (Table 1) .
Histological characteristics
Nineteen low-grade and 24 intermediate-grade neoplasms were identified in this patient population. Thirty-seven patients had single tumours and six patients had two or three tumours resected. The mean size of the largest tumours resected was 43 mm (range 5-170 mm). Vascular, perineural and lymphatic invasion were seen in four, six and eight patients, respectively. Eighteen patients had lymph node metastases. The mean number of lymph nodes resected was seven (range 0-38) ( Table 1) .
Outcomes
After a median follow-up of 68 months, 5-year OS, DSS and DFS were 91%, 94% and 72%, respectively ( Fig. 1 ). Median OS, DSS and DFS were not reached. Three patients had local or regional recurrence and four were diagnosed with distant recurrence during follow-up. Four of these seven patients had undergone R0 resections. Median time to recurrence was 24 months (range 4-96 months) and median survival after recurrence was 49 months. The onset of disease recurrence was associated with worse overall survival (P = 0.012).
Prognostic factors
On univariate analysis, variables associated with worse DSS were size Ն5 cm (P = 0.041) and lymphovascular invasion (P = 0.044). Multivariate analysis was not undertaken because of the limited sample size and number of events. Variables associated with worse DFS on univariate analysis were tumour size Ն5 cm (P = 0.032), positive resection margin (P < 0.0001), lymph node metastasis (P = 0.007) and perineural invasion (P = 0.014) ( Tables 2 and 3) .
Scoring system
The variables of tumour size Ն5 cm, intermediate histological grade, positive margin, nodal metastases, vascular invasion and perineural invasion were analysed as three-or four-variable scoring systems. A scoring system giving one point each for tumour size Ն5 cm, intermediate histological grade, presence of lymph node metastases and resection margin positivity (SGNM) was found to have the strongest association with DSS and DFS. To permit optimal discrimination of outcomes, this scoring system Median length of stay, days 7
Median follow-up of survivors, months 68 SD, standard deviation 
Discussion
Optimal treatment guidelines for pancreatic neuroendocrine neoplasms are obfuscated by their relative rarity and indolence. It is evident that patients with localized neoplasms are more likely to undergo attempted resection and have significantly better prognoses than patients with locally advanced or metastatic neoplasms. 12, 13 Most studies that have attempted to define prognostic criteria for pancreatic neuroendocrine neoplasms have included patients with localized and metastatic neoplasms; as a result, their findings may have limited applicability for patients with localized disease. 4, 5, [13] [14] [15] The World Health Organization system divides pancreatic neuroendocrine neoplasms into well-differentiated neuroendocrine tumours, well-differentiated neuroendocrine tumours of uncertain behaviour, well-differentiated pancreatic neuroendocrine carcinomas and poorly differentiated neuroendocrine carcinomas. 16, 17 This system incorporates the presence of metastases, gross invasion, tumour diameter, angio-invasion, mitoses and proliferative index. It has been criticized for being based more on expert opinion than on published data, 5 and has limited utility for the subset of patients undergoing complete gross resection of pancreatic tumours. Bilimoria et al. 12 used the National Cancer Database to validate the American Joint Committee on Cancer (AJCC) classification system for pancreatic adenocarcinomas for prognostication of pancreatic neuroendocrine neoplasms. They reported that tumour size and the presence of lymph node and distant metastases can be used to reliably stratify operatively managed and non-operatively managed pancreatic neuroendocrine patients according to 5-and 10-year survival. 12 Similarly, the European Neuroendocrine Tumour Society and Rindi et al. examined the use of the tumor node metastasis (TNM) system for all gastroenteropancreatic neuroendocrine tumours. 8, 18 In the present study, we focused on patients undergoing resection of localized pancreatic neuroendocrine neoplasms and determined that tumour size, histological grade, lymph node metastases and resection margin status can be combined in a simplified prognostication system (SGNM) that correlates with risk for disease recurrence (P = 0.0004) and death (P = 0.0006). This scoring system demonstrates a strong predictive ability to discriminate DSS and DFS outcomes as measured by its c-indices of 0.797 and 0.814, respectively. These quantitative measures of predictive ability compare very favourably with c-indices that have been calculated for novel prognostic nomograms developed to predict individual outcomes for patients with pancreatic adeno- Statistically significant values are shown in bold SGNM, tumour size, grade, lymph node status, resection margin status; DFS, disease-free survival Figure 2 Disease-specific survival according to SGNM score in 43 patients undergoing potentially curative resection of primary pancreatic neuroendocrine neoplasms (P = 0.006). SGNM, size, grade, lymph node status, resection margin status Figure 3 Disease-free survival according to SGNM score in 43 patients undergoing potentially curative resection of primary pancreatic neuroendocrine neoplasms (P = 0.004). SGNM, size, grade, lymph node status, resection margin status carcinoma (0.64), 19 hepatocellular carcinoma (0.74), 20 extremity sarcoma (0.77) 21 and gastric adenocarcinoma (0.80). 22 This SGNM scoring system is more effective in discriminating differential outcomes for disease recurrence than for diseaserelated mortality. This probably reflects the paucity of patients who died over the course of follow-up in our study. Indeed, after a median follow-up of 68 months, 5-year OS and DSS rates were 91% and 94%, respectively. By contrast, our own recent analysis of patients undergoing resection of hepatic neuroendocrine metastases identified a 5-year OS of 65%. 23 In previous studies that have grouped patients with localized and advanced or metastatic pancreatic neuroendocrine neoplasms together, 5-year survival has ranged between 49% and 93%. 2, 4, 5, 10, 14, 15, 24 We observed that tumour size >5 cm correlated with DSS and DFS on univariate analysis (P = 0.041 and P = 0.032, respectively). Other authors have similarly reported that tumour size correlates with survival on univariate, but not multivariate, analysis. 4, 5, 15 The prognostic relevance of tumour necrosis and mitotic rate were previously validated by Hochwald et al., who used these histological factors to classify pancreatic neuroendocrine neoplasms into low and intermediate grades that correlate with survival. 4, 25 These same criteria have also been shown to be prognostically important for resected hepatic neuroendocrine neoplasms. 23 In the present study, the association between histological grade (using these same criteria) and disease recurrence neared but did not reach statistical significance (P = 0.091). However, inclusion of histological grade in our proposed classification scheme permitted more accurate prognostication of DSS (P = 0.123 without grade, P = 0.006 with grade) and better discrimination of differences in DFS (data not shown). The presence of vascular invasion and that of perineural invasion were independently associated with worse DSS and DFS, respectively; however, inclusion of these pathological parameters did not improve the ability of the scoring system to discriminate expected survival or recurrence outcomes (data not shown).
We observed a significant correlation between nodal metastases and DFS, and including this parameter into our scoring system enhanced prognostication of both DSS and DFS (data not shown). Lymph node ratio (defined as the ratio of positive lymph nodes to the total number of lymph nodes examined) was also prognostically relevant, but its inclusion did not improve the prognostic strength of our scoring system over that seen with nodal status alone (data not shown). In a study of 29 patients with resected pancreatic neuroendocrine neoplasms, Sarmiento et al. reported a statistically significant association between lymph node metastases and OS. 24 As stated above, the pancreatic adenocarcinoma AJCC TNM staging system, which incorporates the presence of nodal metastases, has also been found to have some utility for pancreatic neuroendocrine neoplasms. 8, 12, 18 Previous analysis has demonstrated that the presence of lymph node metastases does not correlate with tumour size; 4 this biological independence may explain its utility as an independent variable in our proposed SGNM scoring system.
We observed a strong association between positive resection margins and worse DFS (P < 0.001), whereas the association between positive resection margins and DSS neared but did not reach statistical significance (P = 0.074). Few other studies have examined the prognostic impact of this variable. In a study of 60 patients with resected pancreatic neuroendocrine neoplasms with and without distant metastases, Phan et al. found margin status to be the most powerful predictor of survival; the impact of margin status on survival of patients without metastases was not reported. 2 In a recent study of patients undergoing partial hepatectomy for hepatic neuroendocrine neoplasms, margin status was also associated with survival. 23 Our study is clearly limited by its relatively small sample size, its reliance on a single-institution database, and the retrospective nature of its data collection. As a result, our proposed SGNM scoring system will require validation either prospectively or with larger datasets. Perhaps as a result of the small number of deaths in our series (despite its 68-month follow-up), the scoring system appears to have more utility for the prediction of recurrence than death. Importantly, the onset of disease recurrence portended an adverse outcome, as recurrence was associated with decreased survival (P = 0.012). Given the prolonged survival that is to be expected in patients undergoing resection of pancreatic neuroendocrine neoplasms, further discrimination of differences in DSS will probably require a larger sample size and longer follow-up. We did not examine the prognostic value of tumour secretory function because the majority of previous studies have not shown an association. 4, 14, 26, 27 Although some authors have reported that functional tumours have better prognoses than non-functional neoplasms, 26, 28, 29 this finding probably reflects symptoms produced by hormone secretion, which lead to earlier diagnosis and smaller tumour size at the time of resection. 2, 4, 24 Finally, we were unable to control for utilization of postoperative oncological therapies in this retrospective analysis. However, in light of the paucity of effective adjuvant therapies available for patients with resected pancreatic neuroendocrine neoplasms, 30 it is unlikely that the use of such treatments would have significantly altered the course of post-resection survival.
In conclusion, we propose a simple SGNM scoring system that utilizes the reproducible and readily evaluable parameters of tumour size Ն5 cm, histological grade, nodal metastases and resection margin status to stratify patients who are undergoing potentially curative resection of pancreatic neuroendocrine neoplasms according to their risk for recurrence and death.
